upcoming glp 1 drugs Market Overview: GLP-1 Agonists and the Obesity Market | Blog New GLP-1 Guidelines for Type

Gonzlez-Santana A, Estvez-Herrera J, Seward EP, et al

GSK (2017)

These drugs are currently FDA-approved for type 2 diabetes and obesity not for alcohol use disorder

This indicates that the biased agonism properties of tirzepatide, which preferentially activates specific signaling pathways, enhance its ability to stimulate insulin secretion [17, 18]

The medication does not lose effectiveness over time in the same way phentermine does, because it works through hormonal pathways that do not develop the same kind of tolerance

American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity